Technology facilitating single cell cloning to help meet regulatory requirements
Patricia Fitzpatrick Diamond discusses recent technological advances aiding single cell cloning, including Solentim’s VIPS™, in GEN.
To meet regulatory standards, recombinant proteins must be produced from a single cell line, demonstrating monoclonality whilst maintaining viability. This is a slow and involved process, with commonly used methods exhibiting significant draw backs. Limiting dilution retains the viability of cells but is highly inefficient and has large variability of monoclonality, whereas flow cytometry is efficient with strong evidence of monoclonality but often results in poor cell viability.
These challenges have resulted in significant technological developments, driven by a genuine need in the biopharma community. One such solution is Solentim’s Verified In-situ Plate Seeding (VIPS™) single-cell cloning system. VIPS is an all-in-one system combining gentle seeding of single cells followed by immediate imaging of the whole well to confirm arrival of a single cell in the well, resulting in a highly efficient, regulatory compliant method for single cell line production.
In a recent article for GEN, Patricia Fitzpatrick Diamond discusses the challenges associated with single isolation for cell line development and the recent advances in technology, including VIPS, which are helping biotech companies overcome these problems and increase their workflow process efficiency. Read the full article.
If you would like more information on how the VIPS system can help your single cell cloning needs, please get in touch.